Rasor Consulting Group Medical Product Development, Invention to Market

PUBLICATIONS

PATENTS

  1. Rasor NS, Rasor JS. Methods and apparatus for relieving headaches, rhinitis and other common ailments, United States Patent 7,017,573, Mar 28, 2006 (CAPNIA®)
  2. Rasor JS, Rasor NS. Method and apparatus for co-application of gases and drugs to potentiate their action in relieving headaches, angina, and other ailments, United States Patent 6,959,708, Nov 1, 2005
  3. Rasor NS, Rasor JS. Method and apparatus for transcutaneous infusion of carbon dioxide for local relief of pain and other ailments, United States Patent 6,652,479, Nov 25, 2003
  4. Rasor JS, Tickner EG. Method of production and use of microbubble precursors. United States Patent 4,681,119, Jul 21, 1987
  5. Rasor JS, Tickner EG. Microbubble precursors and apparatus for their production and use. United States Patent 4,657,756, Apr 14, 1987
  6. Rasor JS, Tickner EG. Microbubble precursors and methods for their production and use. United States Patent 4,442,843, Apr 17, 1984 (ECHOVIST®, Schering, AG marketed since 1991)
  7. Rasor JS, Rasor NS, Pereira G. Methods and apparatus for the enhanced delivery of physiologic agents to tissue surfaces. 11/340,410 Jan 25, 2006
  8. Keast T, Rasor JS, Loomas BE, Haugaard D, Roschak EJ. Methods for treating chronic obstructive pulmonary disease. 11/357,639 Feb 16, 2006
  9. Rasor NS, Rasor JS. Methods for treating headaches. Jun 16, 2006
  10. Rasor NS, Rasor JS. Methods for treating rhinitis and conjunctivitis.
  11. Rasor NS, Rasor JS. Methods for treating trigeminal neuralgia. Jun 16, 2006
  12. Rasor JS, Rasor NS, Pereira G. Methods and apparatus for treating rhinitis. 11/459,798 Jul 25, 2006
  13. Danek C, Behl RS, Rasor J. Vascular sheaths and methods for their deployment. 60/821,002 Aug 1, 2006
  14. Others pending

PAPERS, BOOK CHAPTERS, AND ABSTRACTS

  1. DeMaria AN, Bommer W, Rasor JS, Tickner EG, Mason DT. Determination of cardiac output by two-dimensional contrast echocardiology. 1981. Hans Rijsterborgh Editor Martin Nijoff Publishers, The Hague p.245.
  2. DeMaria AN, Bommer W, Takeda P, Mason DT, Kwan OL, Rasor JS. Value and limitations of contrast echocardiography in cardiac diagnosis. Noninvasive Diagnostic Methods in Cardiology. 1983. Nobel O. Fowler Editor, F.A. Davis Company Publishers, Philadelphia, p. 167.
  3. Tickner EG, Sahines TP, Rasor JS, Griffin DW, Tucker CR, Popp RL. Noninvasive assessment of pulmonary hypertension using bubble ultrasonic ringing pressure (BURP) method. National Institutes of Health Bethesda, MD. June 1976-August 1981; final Report HR-62917.
  4. Enzmann DR, Lyons BE, Carroll B, Placone RC, Rasor JS, Britt RH, Buston J, Wilson D. Contrast enhanced ultrasound imaging of experimental brain abscesses: HRUS, CT, and neuropathologic correlation. Amer J Neuroradiology. 1982 Jan/Feb;3:41.
  5. Carroll B, Young SW, Rasor JS, Briller R, Cassel D. Ultrasonic contrast enhancement of neoplastic and normal tissue following intravascular encapsulated microbubbles. Radiology. 1982;143:747.
  6. DeMaria AN, Bommer B, Takeda P, Mason DT, Kwan OL, Rasor JS. Value and limitations of contrast echocardiography in cardiac diagnosis. J Cardiography. 1983 Mar;13:1.
  7. Frizsch TH, Lange L, Shartel M, Hillman J, Rasor JS, Reiser J. The characteristics of the new safe nonlung-crossing echocontrast agent SH 454 for reproducible and homogenous opacification of blood and myocardium. Eur heart J. 1984;5(Suppl 1):197.
  8. Osterle S, Sahines T, Tucker C, Tickner EG, Rasor JS, Kernoff R, Kantrowitz N, Billingham M, Wagner L, Popp RL. A new method for assessing right-sided heart pressures using encapsulated microbubbles - A preliminary report. The Western J Med. 1985 Oct;143:463.
  9. Rasor JS. Review of catheter-related infection rates: comparison of conventional catheter materials with Aquavene. J Vascular Access Networks (JVAN). 1991 Spring;1(3):8.
  10. Rasor JS. Landmark midline catheter performance: Analysis of an 830 catheter database. White paper available from Menlo Care, Inc., Menlo Park, CA. 1991 Jul;1(3):1-9.
  11. Rasor JS. Producing a white paper: A parallel path making clinical data available before publication. Amer Med Writers H. 1991 Dec;6(4):12.
  12. Sheehan AM, Palange K, Rasor JS, Moran. Significantly improved peripheral IV catheter performance in neonates: Insertion ease, dwell time, complication rate, and costs. J Perinatology. 1992;12(4):369.
  13. Harwood IR, Greene LM, Kozakowski-Koch JA, Rasor JS. New peripherally-inserted midline catheter: A better alternative for intravenous antibiotic therapy in patients with cystic fibrosis. Pediatric Pulmonology. 1992;12(1):233.
  14. Rasor JS. Transurethral needle ablation treatment or benign prostatic hyperplasia: Comparable results in animals and ex vivo human prostates. White paper available from VIDAMED, Inc., Menlo Park, CA. 1993 Mar:1-10.
  15. Rasor JS, Zlotta AR, Edwards SD, Schulman CC. Transurethral needle ablation (TUNA): Thermal gradient mapping and comparison of lesion size in a tissue model and in patients with benign prostatic hyperplasia (BPH). European Urology. 1993;24(3):415-23.
  16. Goldwasser B, Ramon J, Engelberg S, Ohad D, Sharkey H, Strul B, Rasor JS, Edwards SD: Transurethral needle ablation (TUNA) of the prostate using low-level radiofrequency energy: An animal experimental study. European Urology. 1993;24(3):400-5.
  17. Ramon J, Goldwasser B, Shenfeld O, Engelberg S, Rasor JS, Edwards SD: Needle ablation using radiofrequency current as a treatment for benign prostatic hyperplasia: Experimental results in ex vivo human prostate. European Urology. 1993;24(3):406-10.
  18. Schulmann CC, Zlotta AR, Rasor JS, Hourriez L, Noel JC, Edwards SD. Transurethral needle ablation (TUNA): Safety, feasibility, and tolerance of a new office procedure for treatment of benign prostatic hyperplasia. European Urology. 1993;24(3):415-23.
  19. Rasor JS. The GyneSys Dx catheter system within a system: a single-visit procedure to diagnose and treat uterine and tubal disorders. White paper available from OvaMed Corporation, Sunnyvale, CA. 1994 May:1-8.
  20. Rasor JS, Antonnian F, Glick JM. Multi and single electrode electosurgery for partial meniscectomy: Comparison of depth of injury and ablation rate. White paper available from ArthroCare Corporation, Sunnyvale, CA. 1995 June:1-9.
  21. Rasor JS. Radially expandable laproscopic access device: A controlled comparison of complication rate, effectiveness, and cost. White paper available from InnerDyne Medical, Inc., Sunnyvale CA. 1995 August: 1-10.
  22. Rasor JS, Sun X, Sahm R, Rasor NS. Nasal carbon dioxide for treatment for migraine headache in a multicenter, randomized, double-blind, parallel- and crossover-controlled study. White paper available from CAPNIA, Inc., Los Gatos, CA. 2002 May 23: 1-10
  23. Rasor JS, Rasor NS. CAPNIA phase II migraine study - interim results. White paper available from CAPNIA, Inc., Los Gatos, CA. 2002 Dec 31: 1-2
  24. Rasor, JS. Validation of use of RV, FVC, and mMRC as primary endpoints in studies of treatments for emphysema and determination of the minimal clinically important difference (MCID) for RV using data from over 1,900 subjects. Broncus Technologies, Inc. White Paper. 2005 Oct 19: 1-39
  25. Rasor, JS. Minimal clinically important difference (MCID) in residual volume using data from over 2,600 subjects. Broncus Technologies, Inc. White Paper. 2005 Nov 28: 1-7
  26. Rasor, JS. Use of Sham Controls in Clinical Trials. Broncus Technologies, Inc. White Paper. 2006 March: 1-12
  27. Rasor, JS. Broncus Exhale DES Risk vs. Benefit Assessment. Broncus Technologies, Inc. White Paper. 2006 April: 1-4
  28. Rasor, JS. Minimal clinically important difference (MCID) in residual volume/total lung capacity (RV/TLC) ratio as an endpoint using data from over 2,600 subjects. Broncus Technologies, Inc. White Paper. 2006 May 5: 1-7
  29. Rasor JS, Hill JD, Rodvien R. A quantitative ex vivo model to evaluate thrombosis on biomaterials. ASAIO. 1975 Apr;23rd Annual Meeting.
  30. Rasor JS, Foerster J, Gee P, Vera Z, Mason DT. Vernacular fibrillation threshold decreases with moderate levels of ethanol: computer-controlled determination in the closed chest dog. The Physiologist. 1979 Aug;22(4).
  31. Foerster J, Rasor JS, Gee P, Vera Z, Mason DT. Deleterious effects of alcohol upon ventricular fibrillation threshold: computer-controlled determination in the closed chest dog. Amer Heart Assoc. 1980 Nov;52nd Scientific Sessions.
  32. Bommer W, Tickner EG, Rasor JS, Grehl T, Mason DT. Development of a new echocardiographic contrast agent capable of pulmonary transmission and left heart opacification following peripheral venous injection. Amer Heart Assoc. 1980 Nov;53rd Scientific Sessions.
  33. Bommer W, Rasor JS, Tickner EG, Takeda P, Miller L, Lee G, Mason DT, DeMaria AN. Quantitative regional myocardial perfusion scanning with contrast echocardiography. Amer College Cardiol. 1981 Mar;30th Annual Scientific Session.
  34. Armstrong WF, Kinnney EL, Mueller TM, Rasor JS, Tickner EG, Dillon JC, Feigenbaum H. Contrast echocardiography for the detection of myocardial perfusion abnormalities. Amer Heart Assoc 54th Scientific Sessions, November 1981.
  35. Tucker c, Sahines T, Rasor JS, Wagner L, Kantrwitz N, Tickner EG, Popp R. Noninvasive right ventricular pressure measurement by microbubble oscillation. Amer Hear Assoc 54th Scientific sessions, November 1981.
  36. Rasor JS, Griffin D, Bommer W, Takeda P, Mason DT, DeMaria AN. Visualization of myocardial perfusion by intraaortic injection of ultrasonic contrast agents. Amer College Cardiol 31st Annual Scientific Session, April 1982.
  37. Waltimire B, Rasor JS. Midline catheter: Virtually bloodless insertion technique and needle safety tube minimize potential for transmission of bloodborne disease. Sponsored by national Foundation for Infectious Diseases. 5th National forum on AIDS, Hepatitis, and other blood-borne diseases. Atlanta, GA, March, 1992.
  38. Rasor JS. Safety and effectiveness of a midline catheter in hospital and home care AIDS patients: A better choice than multiple peripheral restarts and central lines. Frontline Healthcare Workers: A National Conference on Prevention of Device Mediated Bloodborne Infections. Sponsored by UA Department of Health and Human Services, CDC, FDA, and OSHA. Washington DC, August 18, 1992.
  39. Rasor JS, Waltimire B. Midline catheter safety features and performance: 1,277 insertions indicate a better alternative than multiple peripheral restarts and central lines. Frontline Healthcare Workers: A National Conference on Prevention of Device Mediated Bloodborne Infections. Sponsored by US Department of Health and Human Services, CDC, FDA, and OSHA. Washington DC, August 18, 1992.
  40. Rasor JS. Safety and effectiveness of a midline catheter in hospital and home care AIDS patients: A better choice than multiple peripheral restarts and central lines. Infectious Diseases society of America Annual Meeting, Anaheim, CA, October 11, 1992.
  41. Schulman CC, Zlotta AR, Rasor JS, Hourriez L, Noel JC, Edwards SD. Transurethral needle ablation (TUNA): Safety, feasibility, and tolerance of a new office procedure for treatment of benign prostatic hpyerplasia (BPH). Western Section Amer Urol Assoc, Palm Desert, CA, Nov 14-18, 1993.
  42. Schulman CC, Zlotta AR, Rasor JS, Hourriez L, Noel JC, Edwards SD. Transurethral needle ablation (TUNA): Safety, feasibility, and tolerance of a new office procedure for treatment of benign prostatic hyperplasia (BPH). 11th world Congress on Endourology, Florence, Italy, Oct 20-23, 1993.

SELECTED PRESENTATIONS

  1. Activities Critical for Transition from Research to Development - Medical Devices, Technical Challenges Relating to an IND, First Symposium for Early Stage Biotechnology and Pharmaceutical Companies, San Jose BioCenter, San Jose, CA, February 2005
  2. Regulatory Issues with Medical Devices, Case Studies, Regulatory Approvals Workshop, UC Berkeley Center for Executive Development Haas School of Business BioEntrepreneurship Certificate Course, September 9, 2004
  3. Medical Product Development, speaker for MBA class of George Foster, Wattis Professor of Management, Graduate School of Business, Stanford University April 2004
  4. Healthcare Company Presentations Dinner, Judge: Julia S. Rasor, Medical Product Development Consultant, International AngelInvestors.org - Silicon Valley, Wilson Sonsini Goodrich & Rosati, Palo Alto, CA, Mar 16, 2004
  5. Retention: Being the Employer of Choice, Northern California Human Resources Association (NCHRA) Life Sciences Professional Emphasis Group (PEG) Conference, San Francisco, CA, February 24, 2004
  6. What Gets Funded - A CEO's Perspective, Woman's Technology Cluster, San Francisco, CA, April 2, 2003
  7. What Gets Funded - A CEO's Perspective, International Angel Investors, Palo Alto, CA, March 15, 2003
  8. Investment Trends by Sector: Biotech/Med; Internet/Software; Semiconductor-Communication, www.Angelinvestors.org, Mentoring, Money, Marketing, International Gathering of Angels, Palo Alto, CA, September 21-23, 2000
  9. How to Keep Your Consulting Business Flourishing, Women In Consulting (WIC), San Carlos, CA, Aug 17, 2000
  10. Producing a White Paper For a Medical Product - A Parallel Fast Track Path Making Clinical Data Available Before Publication, Biomedical Marketing Association/Clinical Laboratory Managers Association (BMA/CLMA) Conference, Anaheim, CA, June 26, 2000
  11. Forecasts: Finance and Technology Trends, Life Sciences, International Angel Investors, Palo Alto, CA, Jan 19, 2000
  12. Stock As Incentive Compensation, Human Resources Consultants Association (HRCA), Sunnyvale, CA, Nov 13, 1999
  13. Stock As Incentive Compensation, Forum of Women Entrepreneurs (FWE) In-Home Networking Events, Los Gatos, CA, July 26, 1999
  14. Is There a Fast Track to FDA Approval? Institute of International Research, Boston, MA, April 15, 1999



  2007 Rasor Consulting Group. All Rights Reserved.